Jack E. Smith

Questioning a Class Effect: Does ACE Inhibitor Tissue Penetration Influence the Degree of Fibrinolytic Balance Alteration following an Acute Myocardial Infarction?

D. Fike, J. Tsikouris, J. Suarez, 2004, Journal of clinical pharmacology.

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

R. Califf, E. Topol, P. Armstrong, 1998, Journal of the American College of Cardiology.

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.

G. Levine, J. Tcheng, D. Cohen, 2002, The American journal of cardiology.

A Randomized Trial of Intravenous Heparin in 12 (Anisoylated Plasminogen Streptokinas Complex) in Nuae Myocardial Infarction : The Duke Clinical Cardiology Study (_1J_CCS) I 11action With Activator University THE DUCCS GROUP*

R. Califf, S. Roark, Kerry L Lee, 2016 .

The effect of diabetes on restenosis

R. Califf, C. O'connor, C. Nelson, 1991 .

Predicting the risk of abrupt vessel closure after angioplasty in an individual patient.

R. Califf, C. Nelson, J. Tcheng, 1994, Journal of the American College of Cardiology.

A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.

C. O'connor, S. Roark, J. Smith, 1994, Journal of the American College of Cardiology.